A new blood test is being called a game changer for helping diagnose Alzheimer’s, and UNLV helped contribute research to it.

Data provided by UNLV researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with cognitive decline.

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

The Lumipulse blood test is made by Japanese company, Fujirebio Diagnostics, which markets a similar Alzheimer's test that measures cerebrospinal fluid collected by spinal tap.

According to the FDA’s press release, the Lumipulse blood test works by measuring the amount of pTau 217 and beta-amyloid 1-42 in the plasma of the blood.

The first-ever blood test to detect Alzheimer’s disease has been cleared by the U.S. Food and Drug Administration (FDA). In a Friday press release, the agency announced its approval of the first ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...